Gilead Sciences
Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery
Second Genome will use its Microbiome Analytics platform to identify novel biomarkers linked to clinical responses to Gilead's investigational medicines.
The international firm is one of several pharmaceutical companies emphasizing new single-cell technologies to improve existing drugs and find new ones.
Biocartis, Kite Sign Development Agreement for Immunotherapy Assays
The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.
The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis.
Yale, Gilead Extend Cancer Collaboration
NEW YORK (GenomeWeb) – The Yale School of Medicine today said that it and Gilead Sciences have extended a research collaboration to identify the genetic and molecular bases of cancer.